This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.
Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.
Immunomedics (IMMU) Reports Interim Urothelial Cancer Data
by Zacks Equity Research
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Is Immunomedics (IMMU) Down 13.1% Since Last Earnings Report?
by Zacks Equity Research
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Earnings Preview: Immunomedics (IMMU) Q2 Earnings Expected to Decline
by Zacks Equity Research
Immunomedics (IMMU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
by Zacks Equity Research
A low key week for the biotech sector with regular drug approvals and pipeline updates.
Do Options Traders Know Something About Immunomedics (IMMU) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
by Zacks Equity Research
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Why Immunomedics (IMMU) Could Be Positioned for a Slump
by Zacks Equity Research
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics (IMMU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunomedics (IMMU) delivered earnings and revenue surprises of -25.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
by Zacks Equity Research
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Implied Volatility Surging for Immunomedics (IMMU) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session
by Zacks Equity Research
Immunomedics (IMMU) shares rose more than 10% in the last trading session, amid huge volumes.
Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock
by Zacks Equity Research
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.